Targeted cancer therapy with Epidermal Growth Factor Receptor (EGFR)-tyrosine kinase inhibitors (TKI), such as Gefitinib and Erlotinib, is revolutionising treatment of non-small cell lung cancer (NSCLC) in patients with activating mutations in EGFR. Another proto-oncogene, KRAS, is mutually exclusive to EGFR mutations and predicts poor response to TKIs, therefore offering an attractive therapeutic target to circumvent intrinsic …